medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 4

<< Back Next >>

Ann Hepatol 2016; 15 (4)

Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation

Yang C, Qin B, Yuan Z, Chen L, Hong-yu Z

Language: English
References: 46
Page: 501-511
PDF size: 175.03 Kb.


ABSTRACT

Introduction and aim. Studies suggest that entecavir and lamivudine are useful as prophylactics against hepatitis B virus (HBV) reactivation in patients undergoing chemotherapy or immunosuppressive therapy, but which drug is more effective is unclear. Here we meta-analyzed available evidence on relative efficacy of prophylactic entecavir or lamivudine therapy in patients with chronic or resolved hepatitis B infection who were undergoing chemotherapy or immunosuppressive therapy. Material and methods. Two reviewers searched PubMed, EMBASE and Google Scholar as well as reference lists in relevant articles to find studies published between January 2005 and May 2015 that met inclusion and exclusion criteria. Data on HBV reactivation, HBV-related hepatitis and all-cause mortality were extracted from the studies and meta-analyzed. Results. A total of eight studies involving 593 patients were included in the meta-analysis, which was performed using a fixed-effect model since no significant heterogeneity was found. Entecavir was associated with significantly lower risk of HBV reactivation than lamivudine (RR 0.29, 95% CI 0.17 to 0.52) as well as lower risk of HBV-related hepatitis (RR 0.11, 95% CI 0.03 to 0.40). The two drugs were associated with similar risk of all-cause mortality (RR 1.12, 95% CI 0.54 to 2.35). Egger’s test suggested no significant publication bias in the meta-analysis. Conclusions. The available evidence suggests that entecavir is more effective than lamivudine for preventing HBV reactivation and HBVrelated hepatitis in patients with chronic or resolved HBV infection who are undergoing chemotherapy or immunosuppressive therapy.


REFERENCES

  1. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.

  2. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 2012; 42: 627-36.

  3. Li X, Lin Q, Dong M, Wen JY, Wei L, Ma XK, Chen ZH, et al. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma 2010; 51: 1678-85.

  4. Villadolid J, Laplant KD, Markham MJ, Nelson DR, George TJ, Jr. Hepatitis B reactivation and rituximab in the oncology practice. Oncologist 2010; 15: 1113-21.

  5. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003; 70: 553-61.

  6. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-11.

  7. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.Hepatology 2006; 43: 209-20.

  8. Yeo W, Hui EP, Chan AT, Ho WM, Lam KC, Chan PK, Mok TS, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J ClinOncol 2005; 28: 379-84.

  9. Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010; 85: 243-50.

  10. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.

  11. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5.

  12. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, Kikuchi M, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of lowdose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44: 339-42.

  13. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.

  14. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivationrelated mortality in chemotherapy patients: a meta-analysis. Liver Int 2008; 28: 28-38.

  15. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009; 94: 998-1005.

  16. Lok AS, McMahon BJ. AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines. Rom J Gastroenterol 2004; 13: 150-4.

  17. Bihl F, Alaei M, Negro F. The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians. Swiss Med Wkly 2010; 140: 154-9.

  18. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15: 89-102.

  19. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28.

  20. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-72.

  21. Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010; 21: 333-7.

  22. Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol 2010; 16: 5447-51.

  23. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39(Suppl. 1): S3-S25.

  24. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration 2011.

  25. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011.

  26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.

  27. Ueda Y, Marusawa H, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res 2013; 43: 67-71.

  28. Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, Zhai LZ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011; 18: 877-83.

  29. Chen FW, Coyle L, Jones BE, Pattullo V. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int 2013; 33: 1203-10.

  30. Huang H, Li XY, Li HR, Shrestha DPR, Guo C-c, Liang CY, Liu T, et al. Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: A prospective study to compare entecavir and lamivudine. J Clin Oncol 2013 ASCO Annual Meeting 2013; 31: 8503.

  31. Tian-biao L, Xing-feng R, Yan C, Jun P, Cheng Y, Zi-wen S. Clinical observation of HBV reactivation and prevention in renal allograft recipients with inactive HBsAg carriers (Chinese).Chinese Journal of Organ Transplantation 2012; 33: 602-5.

  32. Jing H, Xiao-ping C, Xue-fu C, Wen-li C. Clinical observation of preventing and treating HBV reactivation by Lamivudine and Entecavir in patients with non-Hodgkin lymphoma (Chinese). J Pract Med 2011; 27: 2225-7.

  33. Xu-hui X, Xin C. Retrospective analysis of the effect of nucleoside analogues on HBV reactivation due to glucocorticoid therapy (Chinese). Infectious Disease Information 2013; 26: 358-61.

  34. Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, Park MC, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF-alpha agents: a retrospective analysis of 49 cases. Clin Rheumatol 2012; 31: 931-6.

  35. Uchiyama M, Tamai Y, Ikeda T. Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma. Int J Infect Dis 2010; 14: e265-e266.

  36. Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2011.

  37. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.

  38. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.

  39. Raheem OA, Hickey DP. Treatment of hepatitis B virus reactivation in a cadaveric renal transplant recipient with entecavir. Arab J Nephrol Transplant 2013; 6: 41-4.

  40. Colson P, Borentain P, Coso D, Chabannon C, Tamalet C, Gerolami R. Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 2008; 143: 148-50.

  41. Ferreira R, Carvalheiro J, Torres J, Fernandes A, Giestas S, Mendes S, Agostinho C, et al. Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: a case report and literature review. Saudi J Gastroenterol 2012; 18: 277-81.

  42. Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 2009; 51: 1091-6.

  43. Christopeit M, Weber T, Abendroth J, Dollinger M, Lubbert C, Oehme A, Kekule AS, et al. HBs seroconversion in a patient with acute hepatitis B treated with entecavir during immunosuppression against severe bronchiolitis obliterans in the course of chronic graft versus host disease. J Clin Virol 2010; 48: 218-9.

  44. Keam B, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Canc Netw 2011; 9: 465-77.

  45. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007; 85: 16-23.

  46. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-S165.




2020     |     www.medigraphic.com